Summary
A cell line has been derived from a human prostatic carcinoma xenograft, CWR22R. This represents one of very few available cell lines representative of this disease. The cell line is derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft. Flow cytometric and cytogenetic analysis showed that this cell line represents one hyper DNA-diploid stem line with two clonal, evolved cytogenetic sublines. The basic karyotype is close to that of the grandparent xenograft, CWR22, and is relatively simple with 50 chromosomes. In nude mice, the line forms tumors with morphology similar to that of the xenografts, and like the parental CWR22 and CWR22R xenografts, this cell line expresses prostate specific antigen. Growth is weakly stimulated by dihydroxytestosterone and lysates are immunoreactive with androgen receptor antibody by Western blot analysis. Growth is stimulated by epidermal growth factor but is not inhibited by transforming growth factor-β1.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Barranco, M. A.; Alcaraz, A.; Corral, J. M.; Sole, M.; Mallofre, C.; Llopis, J.; Rodriguez, A.; Ribal, M. J.; Alvarez-Vijande, R.; Carretero, P. Numeric alterations in chromosomes 7 and 8 detected by fluorescent in situ hybridization correlate with high-grade localized prostate cancer. Eur. Urol. 34:419–425; 1998.
Brolin, J.; Skoog, L.; Ekman, P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 20:281–295; 1992.
Chah, J. A.; Rhim, J. S. Current status of prostate cancer research: development of in vitro model systems. Int. J. Oncol. 5:1233–1242; 1994.
Cheng, L.; Sun, J.; Pretlow, T. G.; Culp, J.; Yang, N. S. CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy. J. Natl. Cancer Inst. 88:607–611; 1996.
Cui, J.; Deubler, D. A.; Rohr, L. R.; Zhu, X. L.; Maxwell, T. M.; Changus, J. E.; Brothman, A. R. Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet. Cytogenet. 107:51–60; 1998.
Culig, Z.; Klocker, H.; Eberle, J.; Kaspar, F.; Hobisch, A.; Cronauer, M. V.; Bartsch, G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22:11–22; 1993.
Ellis, W. J.; Vessella, R. L.; Buhler, K. R.; Bladou, F.; True, L. D.; Bigler, S. A.; Curtis, D.; Lange, P. H. Characterization of a novel androgensensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin. Cancer Res. 2:1039–1048; 1996.
Gingrich, J. R.; Tucker, J. A.; Walther, P. J.; Day, J. W.; Poulton, S. H.; Webb, K. S. Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J. Urol. 146:915–919; 1991.
Gleave, M.; Hsieh, J. T.; Gao, C. A.; von Eschenbach, A. C.; Chung, L. W. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51:3753–3761; 1991.
Grasso, A. W.; Wen, D.; Miller, C. M.; Rhim, J. S.; Pretlow, T. G.; Kung, H. J. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 15:2705–2716; 1997.
Guo, Y.; Kyprianou, N. Overexpression of transforming growth factor (TGF) beta 1 type II receptor restores TGF-beta 1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 9:185–193; 1998.
Guo, Y.; Wu, Y.; Shinde, S.; Sy, M. S.; Aruffo, A.; Liu, Y. Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J. Exp. Med. 184:955–961; 1996.
Horoszewicz, J. S.; Leong, S. S.; Kawinski, E.; Karr, J. P.; Rosenthal, H.; Chu, T. M.; Mirand, E. A.; Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1809–1818; 1983.
Iizumi, T.; Yazaki, T.; Kanoh, S.; Kondo, I.; Koiso, K. Establishment of a new prostatic carcinoma cell line (TSU-Prl). J. Urol. 137:1304–1306; 1987.
Jenkins, R. B.; Qian, J.; Lee, H. K.; Huang, H.; Hirasawa, K.; Bostwick, D. G.; Proffitt, J.; Wilber, K.; Lieber, M. M.; Liu, W., et al. A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res. 58:759–766; 1998.
Kaighn, M. E.; Narayan, K. S.; Ohnuki, Y.; Lechner, J. F.; Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 17:16–23; 1979.
Katsuoka, Y.; Hoshino, H.; Shiramizu, M.; Sakabe, K.; Seiki, K. Autoradiographic and cytochemical localization of androgen in human prostatic cancer cell lines. Urology 28:228–231; 1986.
Lee, M. S.; Gakovenko, E.; Yun, J. S.; Weijerman, P. C.; Peehl, D. M.; Chen, L. S.; Rhim, J. S. Characterization of adult human prostatic cells immortalized by polybrene-induced DNA transfection with a plasmid containing an origin-defective SV40 genome. Int. J. Oncol. 821–830; 1994.
Marengo, S. R.; Resnick, M. I.; Yang, L.; Chung, J. Y. Differential expression of urinary inter-alpha-trypsin inhibitor trimers and dimers in normal compared to active calcium oxalate stone forming men [see comments]. J. Urol. 159:1444–1450; 1998.
Matturri, L.; Biondo, B.; Cazzullo, A.; Montanari, E.; Radice, F.; Timossi, R.; Turconi, P.; Lavezzi, A. M. Detection of trisomy 7 with fluorescence in situ hybridization and its correlation with DNA content and proliferating cell nuclear antigen-positivity in prostate cancer. Am. J. Clin. Oncol. 21:253–257; 1998.
Mickey, D. D.; Stone, K. R.; Wunderli, H.; Mickey, G. H.; Vollmer, R. T.; Paulson, D. F. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 37:4049–4058; 1977.
Muraki, J.; Addonizio, J. C.; Choudhury, M. S.; Fischer, J.; Eshghi, M.; Davidian, M. M.; Shapiro, L. R.; Wilmot, P. L.; Nagamatsu, G. R.; Chiao, J. W. Establishment of new human prostatic cancer cell line (JCA-1). Urology 36:79–84; 1990.
Nagabhushan, M.; Miller, C. M.; Pretlow, T. P.; Giaconia, J. M.; Edgehouse, N. L.; Schwartz, S.; Kung, H. J.; de Vere White, R. W.; Gumerlock, P. H.; Resnick, M. I., et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Research 56:3042–3046; 1996.
Nagabhushan, M.; Pretlow, T. G.; Guo, Y. J.; Amini, S. B.; Pretlow, T. P.; Sy, M. S. Altered expression of CD44 in human prostate cancer during progression. Am. J. Clin. Pathol. 106:647–651; 1996.
Narayan, P.; Dahiya, R. Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J. Urol. 148:1600–1604; 1992.
Pousette, A.; Carlstrom, K.; Henriksson, P.; Grande, M.; Stege, R. Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research. Prostate 31:198–203; 1997.
Pretlow, T. G.; Delmoro, C. M.; Dilley, G. G.; Spadafora, C. G.; Pretlow, T. P. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res. 51:3814–3817; 1991.
Pretlow, T. G.; Wolman, S. R.; Micale, M. A.; Pelley, R. J.; Kursh, E. D.; Resnick, M. I.; Bodner, D. R.; Jacobberger, J. W.; Delmoro, C. M.; Giaconia, J. M., et al. Xenografts of primary human prostatic carcinoma. J. Natl. Cancer Inst. 85:394–398; 1993.
Schimenti, K. J.; Jacobberger, J. W. Fixation of mammalian cells for flow cytometric evaluation of DNA content and nuclear immunofluorescence. Cytometry 13:48–59; 1992.
Seabright, M. A rapid banding technique for human chromosomes. Lancet 2:971–972; 1971.
Sica, G.; Fabbroni, L.; Dell’Acqua, G.; Iacopino, F.; Marchetti, P.; Cacciatore, M.; Pavone-Macaluso, M. Natural beta-interferon and androgen receptors in prostatic cancer cells. Urol. Int. 46:159–162; 1991.
Stevens, J. W.; Palechek, P. L.; Griebling, T. L.; Midura, R. J.; Rokhlin, O. W.; Cohen, M. B. Expression of CD44 isoforms in human prostate tumor cell lines [see comments]. Prostate 28:153–161; 1996.
Stone, K. R.; Mickey, D. D.; Wunderli, H.; Mickey, G. H.; Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21:274–281; 1978.
Stubbs, A. P.; Lalani, E. N.; Stamp, G. W.; Hurst, H.; Abel, P.; Waxman, J. Second messenger up-regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines, PC-3 and DU-145. FEBS Lett. 383:237–240; 1996.
Tan, J.; Sharief, Y.; Hamil, K. G.; Gregory, C. W.; Zang, D. Y.; Sar, M.; Gumerlock, P. H.; deVere White, R. W.; Pretlow, T. G.; Harris, S. E., et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 11:450–459; 1997.
Tilley, W. D.; Wilson, C. M.; Marcelli, M.; McPhaul, M. J. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res. 50:5382–5386; 1990.
Wainstein, M. A.; He, F.; Robinson, D.; Kung, H. J.; Schwartz, S.; Giaconia, J. M.; Edgehouse, N. L.; Pretlow, T. P.; Bodner, D. R.; Kursh, E. D., et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 54:6049–6052; 1994.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sramkoski, R.M., Pretlow, T.G., Giaconia, J.M. et al. A new human prostate carcinoma cell line, 22Rv1 . In Vitro Cell.Dev.Biol.-Animal 35, 403–409 (1999). https://doi.org/10.1007/s11626-999-0115-4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11626-999-0115-4